Navigation Links
Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
Date:2/20/2008

ed EBITDA was $545.4 million and cash flow from operations was $427.2 million.

"We are pleased with the solid 2007 performance across all of Watson's divisions, particularly the progress made in expanding both our brand and generic product pipelines," began Paul Bisaro, Watson's President and Chief Executive Officer. "We filed 21 ANDAs with the FDA and completed pivotal studies on two exciting new brand products: silodosin for BPH and oxybutynin topical gel for overactive bladder. In addition, in early 2008, FDA accepted our NDA filing for silodosin."

"We continue to make strides on our strategic initiatives aimed at improving our overall cost structure and enhancing operating efficiencies," continued Mr. Bisaro. "In 2007, we achieved more than $30 million in cost savings which resulted from the closure and sale of our Puerto Rico and Phoenix manufacturing facilities, respectively. In addition, our Goa, India facility received FDA clearance to manufacture products for the U.S. market, and we recently shipped our first product made at that facility to the United States. These efforts to improve operating efficiencies will continue in 2008 and beyond, and include the decision to close our Carmel, New York manufacturing facilities by the end of 2010."

"We will continue to build on the momentum we have generated. Our management team and employees recognize the challenges and opportunities in front of us and are committed to drive earnings growth and maximize shareholder value for years to come," concluded Mr. Bisaro.

Fourth Quarter and Full Year 2007 Business Segment Results

Generic Segment Information

Three Months Ended Twelve Months Ended

December 31, December 31,

(Unaudited; $ in thousands) 2007 2006 2007 2006

Generic Segment Contribution

Product sales $343,733 $412,760 $1,408
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Watson to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
3. Watson Receives FDA Approval for Generic Accuneb(R)
4. Watson to Present at the Bear Stearns 20th Annual Healthcare Conference
5. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
6. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
7. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
8. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. Keryx Biopharmaceuticals Announces Additions to Management Team
11. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... primary commercial focus on China , ... C meeting with the U.S. Food and Drug Administration ... February 2015.  During this meeting the Company will seek ...
(Date:12/15/2014)... METTLER TOLEDO is pleased to announce ... V19 with PVM technology , is now available. ... measurement tool continuously captures high-resolution images under a ... automatically prepares a report pairing the most relevant ... changes. This compelling blend of high resolution images ...
(Date:12/15/2014)... , Dec. 15, 2014  GlassesOff Inc. (OTCBB: GLSO) ... as an independent director of the Company,s Board ... AeroScout and served as its CEO until its acquisition ... a $240 million transaction. Recognized as the inventor of ... leadership, AeroScout provided Wi-Fi -based RFID solutions focused on ...
(Date:12/13/2014)... December 13, 2014 CanDiag, Inc., a ... company has changed its name to OncoTab, Inc. ... of where we are today,” said CEO and Chief ... platform’s applications beyond breast cancer diagnostics to include imaging ... of that evolution.” , Founded in 2011 by Dr. ...
Breaking Biology Technology:CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3CanDiag Inc. Expands Product Scope Under a New Name: OncoTab, Inc. 2
... , , , ... Transcriptor Reverse Transcriptase in,the Eberwine Target Preparation Workflow , ... , , Reproducibility and sensitivity are key parameters ... microarray,platforms has shifted the focus to target preparation as a,critical step in microarray ...
... , , ... , , Over the past decade, many organisms ... of gene sequences are now ready,for functional analysis. Knowledge of tissues and cells,that ... , , , , ...
... , , ... Roche Applied Science now offers new larger pack sizes,of PCR-Grade Nucleotides. These larger pack ... , , , Single dNTPs , ... , Single dNTPs are now available in 500-mol pack sizes.,The Deoxynucleoside ...
Cached Biology Technology:Increased Sensitivity in Microarray Analysis 2Increased Sensitivity in Microarray Analysis 3The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 2The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 3The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 4The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 5The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 6PCR-Grade Nucleotides,Larger Pack Sizes Now Available 2
(Date:12/5/2014)... , Dec. 4, 2014 Increased emphasis ... investments in new testing and inspection technologies. The ... rise to a range of innovative test solutions. ... of Generation Y, which is generally more inclined ... result, product development strategies of test equipment vendors ...
(Date:12/3/2014)... GLENDALE, Ariz. , Dec. 2, 2014 ... biometric hand readers, Inception Technologies is pleased to announce ... it easier for customers to collect the workforce data ... the problems that have been left by existing readers. ... to user interface, connectivity and modern technology. Older models ...
(Date:11/21/2014)... Nov. 20, 2014 C-Labs LLC, a leading ... of Things (IoT), today announced the appointment of ... officer. Previously a strategic advisor to the firm, Mr. ... Mr. Traynor is based out of the C-Labs office ... to Chris Muench , Chief Executive Officer. ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... off on a sun-powered adventure this autumn when the Durham ... Challenge. Using nothing but solar power, the DUSC team ... of Australia to Adelaide in the south. The Durham ... in mid-August after taking part in endurance testing in the ...
... Milan, Italy, August 11, 2011 Memory is not a ... on different areas of the brain. Episodic memory, the ability ... is known to be vulnerable to brain damage involving the ... hippocampus occurs very early in life? In a case study ...
... Loligo bleekeri ) employ different reproductive strategies depending on their ... BMC Evolutionary Biology shows that the divergent mating ... different sperm sizes. Large male squid compete for females ... female has chosen her partner they mate in an above ...
Cached Biology News:Durham University solar car takes on World Solar Challenge 2When you can recite a poem but not remember who asked you to learn it a few days earlier 2
Lentigen's manufacturing platform is sufficiently versatile for use in the manufacture of any HIV-based Lentiviral vector. Lentigen will manufacture your LV of choice to the highest possible titer a...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: